Description

Docetaxel (Docetaxel) Concentrate for Solution for Infusions 10 mg/ml. 8 ml. (80 mg.) Vial №1

Ingredients:

Each vial contains 80 mg of Docetaxel in a concentrate solution for infusion.

Dosage:

The recommended dosage of Docetaxel for adults is usually 75 mg/m² administered intravenously over 1 hour every 3 weeks.

Indications:

Docetaxel is indicated for the treatment of various types of cancers including breast cancer, non-small cell lung cancer, prostate cancer, and gastric adenocarcinoma.

Contraindications:

Docetaxel is contraindicated in patients with a history of severe hypersensitivity reactions to Docetaxel or other drugs formulated with polysorbate 80.

Directions:

Docetaxel should only be administered under the supervision of a qualified healthcare provider experienced in the use of cytotoxic chemotherapy.

Scientific Evidence:

Docetaxel has shown significant efficacy in various clinical trials for the treatment of different types of cancers. Research studies have demonstrated its ability to inhibit microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

Additional Information:

It is important to monitor patients receiving Docetaxel for potential side effects such as neutropenia, hypersensitivity reactions, and fluid retention. Close monitoring of blood counts is essential during treatment to manage potential hematologic toxicities.

Docetaxel, a member of the taxane family, exerts its pharmacological effects by disrupting microtubule function, ultimately leading to cell death. This mechanism makes it a valuable component in the treatment of various solid tumors.

Comparative studies have shown Docetaxel to be more effective than other chemotherapeutic agents in certain cancer types, highlighting its importance in modern oncology treatment regimens.